Cargando…

A Review of Exenatide: Optimizing Glycemic Control and Associated Cardiovascular Risk Factors in Type 2 Diabetes

Type 2 diabetes mellitus (T2DM) is a well-recognized risk factor for the development of cardiovascular disease. With an increasing prevalence of obesity, this risk has increased further. Management of T2DM in obese patients is particularly challenging as treatment with the majority of glucose-loweri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Htike, Zin Z., Khunti, Kamlesh, Davies, Melanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare Communications 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508112/ https://www.ncbi.nlm.nih.gov/pubmed/22422427 http://dx.doi.org/10.1007/s13300-012-0003-x

Ejemplares similares

Age at diagnosis of type 2 diabetes and cardiovascular risk factor profile: A pooled analysis
por: Barker, Mary M, et al.
Publicado: (2022)

Cardiovascular Determinants of Aerobic Exercise Capacity in Adults With Type 2 Diabetes
por: Gulsin, Gaurav S., et al.
Publicado: (2020)

The Effectiveness of Screening for Diabetes and Cardiovascular Disease Risk Factors in a Community Pharmacy Setting
por: Willis, Andrew, et al.
Publicado: (2014)

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
por: Blonde, Lawrence, et al.
Publicado: (2015)

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Clinical associations with stage B heart failure in adults with type 2 diabetes
por: Gulsin, Gaurav S., et al.
Publicado: (2021)

Dietary Recommendations for the Prevention of Type 2 diabetes: What Are They Based on?
por: Carter, Patrice, et al.
Publicado: (2012)

Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study
por: KÖSEOĞLU, Derya, et al.
Publicado: (2021)

The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies
por: Davies, Melanie, et al.
Publicado: (2016)

Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes
por: Zaccardi, Francesco, et al.
Publicado: (2021)

Cardiovascular events and mortality in people with and without type 2 diabetes: An observational study in a contemporary multi‐ethnic population
por: Coles, Briana, et al.
Publicado: (2020)

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
por: Meloni, Alison R, et al.
Publicado: (2013)

Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis
por: Vetrone, Lorenzo M., et al.
Publicado: (2018)

The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review
por: Ojo, Omorogieva
Publicado: (2016)

Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus
por: Nisal, Kaustubh, et al.
Publicado: (2012)

Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study
por: Zaccardi, Francesco, et al.
Publicado: (2020)

Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes
por: Khunti, Kamlesh, et al.
Publicado: (2015)

Developing a Conceptually Equivalent Type 2 Diabetes Risk Score for Indian Gujaratis in the UK
por: Patel, Naina, et al.
Publicado: (2016)

Prediction of type 2 diabetes risk in people with non-diabetic hyperglycaemia: model derivation and validation using UK primary care data
por: Coles, Briana, et al.
Publicado: (2020)

Impact of Information Technology–Based Interventions for Type 2 Diabetes Mellitus on Glycemic Control: A Systematic Review and Meta-Analysis
por: Alharbi, Nouf Sahal, et al.
Publicado: (2016)

Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
por: Paul, Sanjoy K, et al.
Publicado: (2015)

Walking away from type 2 diabetes: trial protocol of a cluster randomised controlled trial evaluating a structured education programme in those at high risk of developing type 2 diabetes
por: Yates, Thomas, et al.
Publicado: (2012)

Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial
por: Black, James A, et al.
Publicado: (2014)

Exenatide once weekly combined with metformin reduced glycemic variability in type 2 diabetes by using flash glucose monitoring system
por: Li, Yang, et al.
Publicado: (2020)

Calculating the design effect for a cluster stepped-wedge trial with varying cluster size; a case study from a trial in type 2 diabetes
por: Ashra, Nuzhat, et al.
Publicado: (2015)

South Asian individuals at high risk of type 2 diabetes have lower plasma vitamin C levels than white Europeans
por: Carter, Patrice, et al.
Publicado: (2013)

Joint Prevalence of Diabetes, Impaired Glucose Regulation, Cardiovascular Disease Risk and Chronic Kidney Disease in South Asians and White Europeans
por: Khunti, Kamlesh, et al.
Publicado: (2013)

Engagement, Retention, and Progression to Type 2 Diabetes: A Retrospective Analysis of the Cluster-Randomised "Let's Prevent Diabetes" Trial
por: Gray, Laura J., et al.
Publicado: (2016)

The General Practitioner Prompt Study to Reduce Cardiovascular and Renal Complications in Patients With Type 2 Diabetes and Renal Complications: Protocol and Baseline Characteristics for a Cluster Randomized Controlled Trial
por: Willis, Andrew, et al.
Publicado: (2018)

Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug‐naïve type 2 diabetic patients
por: Deng, Hongrong, et al.
Publicado: (2019)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010)

Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)

Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study
por: Inaishi, Jun, et al.
Publicado: (2022)

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
por: Ratner, Robert, et al.
Publicado: (2011)

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
por: Blevins, Thomas, et al.
Publicado: (2016)

Long COVID — metabolic risk factors and novel therapeutic management
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis
por: Carter, Patrice, et al.
Publicado: (2010)

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
por: MacConell, Leigh, et al.
Publicado: (2013)

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
por: Buse, John B., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_32ovbat47ggtva3o4co1odkms2